Agile Therapeutics Inc (FRA:0AL)
€ 7.241 0 (0%) Market Cap: 3.30 Mil Enterprise Value: 2.97 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Q4 2023 Agile Therapeutics Inc Earnings Call Transcript

Mar 28, 2024 / 12:30PM GMT
Operator

Good morning, and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2023 financial results conference call. Please note, today's event is being recorded I would now like to turn the conference over to Matt Reilly, Head of Investor Relations. Please go ahead.

Matthew Riley
Agile Therapeutics Inc - Head of Investor Relations, Corporate Communications

Hello, everyone, and welcome to today's conference call to discuss our fourth quarter and full year 2023 financial results and corporate update.

Before we start, let me remind you that today's call will include forward-looking statements based on our current expectations, including statements concerning our financial outlook and financing prospects for the future, management's expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla and our ability to become cash flow positive, our operating expenses, our business strategy, our partnership with faxes and its ability to promote growth, our product supply agreement with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot